PDF(Pubmed)
Abstract：
Background Antimicrobial resistance by bacteria poses a substantial threat to the success in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Levonadifloxacin is a novel benzoquinolizine subclass of quinolone which has a broad spectrum of activity, available in both oral and intravenous formulations for the treatment of skin structure infections caused by Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Patients and methods This prescription event monitoring study captured data of 227 patients receiving levonadifloxacin (oral and/or IV) in a real-world setting to assess the safety and efficacy in the treatment of ABSSSI. Study outcomes were a clinical and microbial success at the end of therapy and safety was assessed based on adverse events reported. Results One hundred and forty patients received IV levonadifloxacin therapy, 76 patients received oral alalevonadifloxacin, and 11 received IV followed by oral therapy. The mean duration of therapy was 7.3 days. Out of 227 patients, MRSA isolates were identified in 79 patients. Clinical success rates with oral, IV, and IV followed by oral levonadifloxacin therapy were 97.3%, 97.8%, and 100% respectively. The overall microbial success rate was 99.2% and only two patients reported two adverse events. Conclusions The excellent safety and efficacy profile of levonadifloxacin on oral and/or intravenous therapy, makes it a desirable treatment modality for management of ABSSSI. Unique features of levonadifloxacin such as availability of both IV and oral form, minimal drug-drug interactions, exemption from dosage adjustment in renal and hepatic impaired patients and a broad spectrum of coverage, makes it a suitable agent meeting several unmet clinical needs in contemporary patients.
摘要：
背景技术细菌的抗微生物耐药性对急性细菌性皮肤和皮肤结构感染(ABSSSI)的成功治疗构成实质性威胁。左旋阿霉素是喹诺酮类的一种新型苯并喹诺嗪亚类,具有广谱的活性,口服和静脉制剂均可用于治疗由革兰氏阳性病原体引起的皮肤结构感染，包括耐甲氧西林金黄色葡萄球菌（MRSA）。患者和方法该处方事件监测研究捕获了227名在现实世界环境中接受左旋那氟沙星(口服和/或IV)的患者的数据,以评估ABSSSI治疗的安全性和有效性。研究结果是治疗结束时的临床和微生物成功，并根据报告的不良事件评估安全性。结果一百四十例患者接受左旋甲氧氟沙星静脉治疗,76例患者接受口服阿替沃纳沙星，11人接受静脉内注射，然后口服治疗。治疗的平均持续时间为7.3天。227名患者中,在79例患者中鉴定出MRSA分离株。口服的临床成功率，IV,和IV，然后口服左旋纳帕沙星治疗为97.3％，97.8%,分别为100%。总体微生物成功率为99.2％，只有两名患者报告了两次不良事件。结论口服和/或静脉内使用左旋地氟沙星具有良好的安全性和有效性,使其成为ABSSSI管理的理想治疗方式。独特的特点，如IV和口服形式的可用性，最小的药物-药物相互作用，免除肾和肝损害患者的剂量调整和广泛的覆盖范围，使其成为满足当代患者几种未满足的临床需求的合适药物。
